Teva Reports Third Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim
November 15, 2016 10:26 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $80 price target on Teva Pharma (NYSE: TEVA) following results. The analyst said concerns that generic sales are disappearing are overdone.
Chen commented, "TEVA reported a 3Q16 beat, underscoring our belief that its execution is still... More
Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook
November 15, 2016 7:01 AM EST(Updated - November 15, 2016 7:05 AM EST)
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.
The company sees Q3 EPS of $1.34 - $1.44 with... More
